Maxim Group investment analysts have begun to cover stocks of Virpax Pharmaceuticals (NASDAQ:VRPX – Get a rating) in a report released Thursday, Fly reports. The company has attached a “buy” rating to the stock.
Separately, ThinkEquity began covering Virpax Pharmaceuticals shares in a research note on Monday, February 28. They set a “buy” rating on the stock.
NASDAQ:VRPX traded down $0.03 during Thursday trading hours, hitting $1.55. 54,276 shares of the company were traded, against an average volume of 107,852. Virpax Pharmaceuticals has a 52-week low of $1.19 and a 52-week high of $36.00. The stock has a 50-day simple moving average of $1.69 and a 200-day simple moving average of $2.44.
In other news, CEO Anthony P. Mack bought 75,750 shares of the company in a transaction that took place on Wednesday, May 18. The shares were purchased at an average price of $1.34 per share, with a total value of $101,505.00. As a result of the purchase, the CEO now directly owns 252,562 shares of the company, valued at approximately $338,433.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, accessible via this link. Insiders have purchased 84,729 shares of the company valued at $113,401 over the past three months.
A number of hedge funds and other institutional investors have recently changed their positions in VRPX. Altium Capital Management LP acquired a new stake in Virpax Pharmaceuticals during the third quarter valued at approximately $1,305,000. Renaissance Technologies LLC acquired a new stake in Virpax Pharmaceuticals during the first quarter valued at approximately $348,000. Citadel Advisors LLC acquired a new stake in Virpax Pharmaceuticals during the fourth quarter valued at approximately $336,000. Geode Capital Management LLC increased its position in Virpax Pharmaceuticals shares by 374.6% during the 4th quarter. Geode Capital Management LLC now owns 47,671 shares of the company worth $163,000 after purchasing an additional 37,626 shares during the period. Finally, Two Sigma Investments LP acquired a new equity stake in Virpax Pharmaceuticals during Q3 worth approximately $123,000. Hedge funds and other institutional investors own 18.90% of the company’s shares.
About Virpax Pharmaceuticals (Get a rating)
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug delivery systems and drug delivery technologies focused on advancing non-opioid, non-addictive pain management therapies and treatments for systemic disorders central nervous. Its preclinical-stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug for the treatment of chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug candidate that enables the delivery of a metabolically labile peptide drug into the brain.
Featured articles
Get news and reviews for Virpax Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Virpax Pharmaceuticals and related companies with MarketBeat.com’s free daily email newsletter.
